Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 16, Issue 7, Pages 613-621
Publisher
Wiley
Online
2014-01-08
DOI
10.1111/dom.12258
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AACE Comprehensive Diabetes Management Algorithm 2013
- (2015) Alan Garber et al. Endocrine Practice
- Metformin + saxagliptin for type 2 diabetes
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
- (2011) Giuseppe Derosa et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
- (2010) E M Migoya et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
- (2010) T. Forst et al. DIABETIC MEDICINE
- Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
- (2010) A. Maida et al. DIABETOLOGIA
- New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
- (2010) Y. M. Cho et al. DIABETOLOGIA
- Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
- (2010) B. Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
- (2009) Debora Williams-Herman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
- (2009) Richard E Pratley EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
- (2008) Itamar Raz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*
- (2008) R. Scott et al. DIABETES OBESITY & METABOLISM
- Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice
- (2008) Yusuke Moritoh et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started